pros and cons of glp-1 drugs Your guide to side effects 🎉A new approach to weight

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

This includes integrating the latest clinical trial data and delving into potential signaling pathways and pharmacological mechanisms

This supplement fits seamlessly into any lifestyle, encouraging regular use alongside balanced nutrition and active habits to help maximize sustainable, long-term wellness results.

Stool softeners don't address the root cause

Learn what patients and prescribers should know about lean mass, protein, and exercise.

Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity